about
Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD studySeverity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of lifeCognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's diseaseVariation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease.Cholinergic dysfunction contributes to gait disturbance in early Parkinson's diseaseBaseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.The spectrum of nonmotor symptoms in early Parkinson disease.Cognitive decline and quality of life in incident Parkinson's disease: The role of attentionVitamin D supplementation in older people (VDOP): Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000 IU, 24,000 IU or 48,000 IU of vitamin D₃.Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD studyAnxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease.The interplay of cholinergic function, attention, and falls in Parkinson's disease.New horizons in the pathogenesis, assessment and management of movement disorders.The incidence of Parkinson's disease in the North-East of England.What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?Review of delirium in patients with Parkinson's disease.Occurrence, management and outcomes of hip fractures in patients with Parkinson's disease.A novel approach to falls classification in Parkinson's disease: development of the Fall-Related Activity Classification (FRAC).Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naïve cohort.Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease.Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.Falling short: underestimation of fracture risk in atypical parkinsonian syndromes.Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms.Rapid eye movement sleep behavior disorder in Parkinson's disease: magnetic resonance imaging study.Cognitive impairment in Parkinson's disease: impact on quality of life of carers.New horizons in multimorbidity in older adults.Poor Sleep Quality and Progression of Gait Impairment in an Incident Parkinson's Disease Cohort.Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study.Quality of life and mild cognitive impairment in early Parkinson's disease: does subtype matter?Primary sleep disorder prevalence in patients with newly diagnosed Parkinson’s disease.Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease?Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment.Short latency afferent inhibition: Effects of ageing.Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?The Role of Vitamin D in Disease Progression in Early Parkinson's Disease.Natural history of falls in an incident cohort of Parkinson's disease: early evolution, risk and protective features.
P50
Q33574058-58E56F5D-39C7-451A-8507-CC0ED5830C97Q33754677-D23AB881-29F5-4BD8-84E8-042C77E19C79Q34174901-EBA7E1C5-6AAE-4173-95CC-F9F54C0C4CDFQ34325640-BA259B63-BE83-4300-A6F8-EAAFE1BBC697Q34382051-BDA3478D-2AEF-4A32-8EFD-F722FC530021Q35532413-D936E2F6-12D6-44C0-A0C9-D0E298715F5FQ36218725-1C079445-910A-4C8E-B9FC-AFF5C3557A49Q36351574-76F6CD9C-7E84-4700-9718-36767D515259Q36659353-F99711D7-971F-41F0-85BD-31639FABA5A0Q37000056-72E3F38B-13F9-421D-87AC-8BEF5A7D9F75Q37359637-55D25A75-85A6-42A4-B3A7-D9B03B76238EQ37593269-BCBC67DC-0B59-4C3C-96F9-16636A18A857Q37682538-3F1E39C6-77EE-4E19-B971-C161861E7C1CQ37928585-17A4AF4B-C3E2-42F0-8673-197CF9BFA3DAQ38036239-78383481-1D37-4438-B069-ECC0C3527F71Q38123589-6834F6D9-E5AC-4E31-A0F7-F59B357CCC3AQ38212033-E3881E94-1EE7-4C8B-8A47-D1EFABA5970CQ38407557-305A31E8-4BA2-42DE-8C69-4308B642E263Q38469040-1F547F6B-6287-4764-8EA3-0F1153D5E340Q38541233-8103B249-F584-46DB-A0F3-C042BECAB696Q38787870-7DA2E6DF-BDFF-4109-8FD3-D98499561A51Q39398312-94CF28EB-659A-46F1-B157-29F21E5741F7Q39901740-4D3315C0-3963-47FE-9509-C16EAD422827Q40568866-977AC342-96E5-4F8C-B872-83236D0BC1EDQ41193294-5DC8B1BE-E3C2-4645-8F1B-D11B4A68BDF0Q43775227-1E5CD409-9E4F-4E7B-A64D-CA37D0D7387DQ45749080-13B2F73E-52A8-47D9-8E38-F9D65D944FBFQ46770992-229F829F-17B4-4EB3-B5A1-D7853E59941FQ47151472-16EAE802-BDC2-4486-9053-87BFEA0460FCQ47250291-5A92113F-010F-4C18-9FAC-527FAAAA709DQ47713769-F7098928-E768-4F22-8B80-1FAE2DC3FF90Q47772883-0E7A5199-A270-4338-9342-0319A8726261Q48073512-AE9F2BEF-FAE5-4EED-A0F0-9F68E22C0F8AQ48129611-2C565ED5-E976-4552-A581-58E7CD200290Q48144471-16B08A8C-8B19-4BC5-A84B-CA9FD7026FEEQ48358858-44D01571-4857-4DCD-A869-23F29D135FEBQ48736866-62E3786C-45FF-48FC-8067-40C87B94B439Q48759416-00C72367-CDA8-4C0D-8482-8AF4F14B8F82Q49300156-22D82ED0-EECC-41AB-B2FC-377F563C618FQ49521363-3AA79C47-12DE-44E4-B4A6-46CB30EE1CBE
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alison J Yarnall
@es
Alison J. Yarnall
@en
Alison J. Yarnall
@nl
type
label
Alison J Yarnall
@es
Alison J. Yarnall
@en
Alison J. Yarnall
@nl
altLabel
Alison Yarnall
@en
prefLabel
Alison J Yarnall
@es
Alison J. Yarnall
@en
Alison J. Yarnall
@nl
P106
P1153
26665224800
P21
P31
P496
0000-0002-3126-9163
P569
2000-01-01T00:00:00Z